Clinical trial

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00095628 · National Cancer Institute (NCI), NIH · Completed

Key facts

NCT number NCT00095628
Title SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Official title A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor National Cancer Institute (NCI), NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity and 12 more
Intervention type Drug, Other
Interventions ispinesib, laboratory biomarker analysis, pharmacological study
Enrollment 21
Start date Jan 1, 2005
Primary completion Jul 1, 2010
Completion Jul 1, 2010
First posted Nov 8, 2004
Last update posted Mar 6, 2017
Countries Canada

At a glance

  • 1–9 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies